zonisamide has been researched along with oxidopamine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gluck, MR; Granson, H; Santana, LA; Yahr, MD | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Kikkawa, Y; Kimoto, N; Miyazaki, I; Miyoshi, K; Murata, M; Takeshima, M | 1 |
| Kanemaru, A; Kojima, T; Tokashiki, S; Ueda, Y | 1 |
| Nambu, A; Sano, H | 1 |
| Kaneko, S; Kusaka, H; Morise, S; Murakami, A; Nakamura, M; Oki, M; Takenouchi, N; Tohge, R; Yakushiji, Y | 1 |
5 other study(ies) available for zonisamide and oxidopamine
| Article | Year |
|---|---|
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Isoxazoles; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Zonisamide | 2004 |
Neuroprotective effects of zonisamide target astrocyte.
Topics: Animals; Antiparkinson Agents; Astrocytes; Basal Ganglia; Carbidopa; Cells, Cultured; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glial Fibrillary Acidic Protein; Glutathione; Isoxazoles; Male; Mice; Mice, Inbred ICR; Nerve Growth Factors; Neuroprotective Agents; Oxidopamine; Parkinson Disease; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Tyrosine 3-Monooxygenase; Zonisamide | 2010 |
Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Gene Expression; Gene Expression Profiling; Isoxazoles; Levodopa; Male; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Zonisamide | 2012 |
The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.
Topics: Animals; Anticonvulsants; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinsonian Disorders; Treatment Outcome; Zonisamide | 2019 |
Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; GABAergic Neurons; Levodopa; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; RNA-Binding Proteins; Serotonergic Neurons; Serotonin Agents; Zonisamide | 2021 |